EU/3/09/641

Table of contents

About

On 15 May 2009, orphan designation (EU/3/09/641) was granted by the European Commission to Atlantic Healthcare Limited, United Kingdom, for alicaforsen for the treatment of pouchitis.

In July 2013, Atlantic Healthcare Limited changed name to Atlantic Healthcare plc.

The sponsorship was transferred to Atlantic Pharmaceuticals (Holdings) Ltd, United Kingdom, in November 2017.

Key facts

Active substance
Alicaforsen
Disease / condition
Treatment of pouchitis
Date of decision
15/05/2009
Outcome
Positive
Orphan decision number
EU/3/09/641

Sponsor's contact details

Atlantic House
12 Rose & Crown Walk
Saffron Walden
Essex CB10 1JH
United Kingdom
Tel. +44 (0)1799 513391
E-mail: ann.mccormack@atlantichc.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating